微生态制剂在炎症性肠病中的应用

Application of microecologics in inflammatory bowel disease

炎症性肠病(inflammatory bowel disease,IBD)是病因尚不十分明确的慢性非特异性肠道炎症性疾病。肠道菌群失调是炎症性肠病发生的重要原因,其通过多种途径调控IBD的发生和发展。微生态制剂可通过调节肠道菌群中有益菌和致病菌的数量和比例,起到缓解IBD病情的作用。微生态制剂形式多样,包括益生菌、抗生素和粪菌移植。不同种类的微生态制剂对炎症性肠病的疗效差异较大,因此微生态制剂既是目前的研究热点也是难点。

Inflammatory bowel disease （IBD） involves chronic inflammation of all or part of digestive tract. IBD is a complex disease which arises as a result of the interaction of environmental and genetic factors, leading to immunological responses and inflammation in the intestine. Intestinal dysbiosis was the key factor of IBD development. Intestinal flora could regulate the initiation and development of IBD in several ways. Microecologics could relieve symptoms through regulating the quantity and proportion of intestinal flora. There were several forms of microecologics, including probiotics, antibiotics and fecal microbiota transplantation （FMT）. The efficacy and safety of different microecologics in IBD treatment were quite difference. So microecologics were the hot point and also the difficult point of IBD researches.